![Tolerability of a New 10% Liquid Immunoglobulin for Intravenous Use, Privigen®, at Different Infusion Rates | Semantic Scholar Tolerability of a New 10% Liquid Immunoglobulin for Intravenous Use, Privigen®, at Different Infusion Rates | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/3bb2e06b418313ce7e5cb9ee9add0b370500469c/5-Figure2-1.png)
Tolerability of a New 10% Liquid Immunoglobulin for Intravenous Use, Privigen®, at Different Infusion Rates | Semantic Scholar
![L-proline-stabilized human IgG: Privigen® 10% for intravenous use and Hizentra® 20% for subcutaneous use | Immunotherapy L-proline-stabilized human IgG: Privigen® 10% for intravenous use and Hizentra® 20% for subcutaneous use | Immunotherapy](https://www.futuremedicine.com/cms/10.2217/imt.10.108/asset/images/medium/figure2.gif)
L-proline-stabilized human IgG: Privigen® 10% for intravenous use and Hizentra® 20% for subcutaneous use | Immunotherapy
![Original and modified processes for the manufacture of the intravenous... | Download Scientific Diagram Original and modified processes for the manufacture of the intravenous... | Download Scientific Diagram](https://www.researchgate.net/publication/308337236/figure/fig1/AS:408420147580932@1474386359596/Original-and-modified-processes-for-the-manufacture-of-the-intravenous-immunoglobulin.png)
Original and modified processes for the manufacture of the intravenous... | Download Scientific Diagram
![L-proline-stabilized human IgG: Privigen® 10% for intravenous use and Hizentra® 20% for subcutaneous use | Immunotherapy L-proline-stabilized human IgG: Privigen® 10% for intravenous use and Hizentra® 20% for subcutaneous use | Immunotherapy](https://www.futuremedicine.com/cms/10.2217/imt.10.108/asset/images/medium/figure1.gif)
L-proline-stabilized human IgG: Privigen® 10% for intravenous use and Hizentra® 20% for subcutaneous use | Immunotherapy
![Incidence rates of probable HA within 10 days of Privigen use by study... | Download Scientific Diagram Incidence rates of probable HA within 10 days of Privigen use by study... | Download Scientific Diagram](https://www.researchgate.net/publication/341870481/figure/tbl1/AS:899946626695169@1591575404955/Incidence-rates-of-probable-HA-within-10-days-of-Privigen-use-by-study-period.png)
Incidence rates of probable HA within 10 days of Privigen use by study... | Download Scientific Diagram
![Tolerability of a New 10% Liquid Immunoglobulin for Intravenous Use, Privigen®, at Different Infusion Rates | Semantic Scholar Tolerability of a New 10% Liquid Immunoglobulin for Intravenous Use, Privigen®, at Different Infusion Rates | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/3bb2e06b418313ce7e5cb9ee9add0b370500469c/4-Figure1-1.png)
Tolerability of a New 10% Liquid Immunoglobulin for Intravenous Use, Privigen®, at Different Infusion Rates | Semantic Scholar
![Tolerability of a New 10% Liquid Immunoglobulin for Intravenous Use, Privigen®, at Different Infusion Rates | Semantic Scholar Tolerability of a New 10% Liquid Immunoglobulin for Intravenous Use, Privigen®, at Different Infusion Rates | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/3bb2e06b418313ce7e5cb9ee9add0b370500469c/5-TableIII-1.png)
Tolerability of a New 10% Liquid Immunoglobulin for Intravenous Use, Privigen®, at Different Infusion Rates | Semantic Scholar
![Tolerability of a New 10% Liquid Immunoglobulin for Intravenous Use, Privigen®, at Different Infusion Rates | Semantic Scholar Tolerability of a New 10% Liquid Immunoglobulin for Intravenous Use, Privigen®, at Different Infusion Rates | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/3bb2e06b418313ce7e5cb9ee9add0b370500469c/3-TableI-1.png)